melatonin and nitrones as potential therapeutic agents for stroke

Clicks: 130
ID: 249925
2016
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Stroke is a disease of aging affecting millions of people worldwide, and recombinant tissue-type plasminogen activator (r-tPA) is the only treatment approved. However, r-tPA has a low therapeutic window and secondary effects which limit its beneficial outcome, urging thus the search for new more efficient therapies. Among them, neuroprotection based on melatonin or nitrones, as free radical traps, have arisen as drug candidates due to their strong antioxidant power. In this Perspective article, an update on the specific results of the melatonin and several new nitrones are presented.
Reference Key
romero2016frontiersmelatonin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Alejandro Romero;Eva Ramos;Paloma Patiño;Maria J. Oset-Gasque;Francisco López-Muñoz;Francisco López-Muñoz;José Marco-Contelles;María I. Ayuso;Alberto Alcázar
Journal Frontiers in chemistry
Year 2016
DOI 10.3389/fnagi.2016.00281
URL
http://journal.frontiersin.org/article/10.3389/fnagi.2016.00281/full
Keywords
stroke oxidative stress neuroprotection melatonin neuropsychiatry biological psychiatry

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.